Biotech Analysis Central Pharma News: Regeneron's Flop, Viking's Trial Success, Biogen's MS Deal


Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. News: On Monday November 27, 2017 Regeneron Pharmaceuticals announced that it would stop development of a drug combination between Eylea and nesvacumab.



from Biotech News